Drug
Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321) is a pharmaceutical drug with 2 clinical trials. Currently 2 active trials ongoing.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(100%)
Phase Distribution
Ph phase_4
1
50%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution1 total trials
Phase 4Post-market surveillance
1(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
2
all time
Status Distribution
Active(2)
Detailed Status
Active, not recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
2
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 41 (100.0%)
Trials by Status
active_not_recruiting150%
recruiting150%
Recent Activity
2 active trials
Showing 2 of 2
active_not_recruiting
The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
NCT06075147
recruitingphase_4
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
NCT06662994
Clinical Trials (2)
Showing 2 of 2 trials
NCT06075147
The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
NCT06662994Phase 4
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2